

Error! Reference source not found.  
Serial No. unknown

**REMARKS**

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page/s is/are captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



Arthur R. Crawford  
Reg. No.25,327

ARC:ecb  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE CLAIMS**

5. A method according to ~~any of~~ claims 1-4, wherein said cells are immune cells.

6. A method according to ~~any of~~ claims 1-4, wherein said cells are non-immune cells.

7. A method according to ~~any of~~ claims 1-6, wherein said cells express shared immunodominant cancer antigens.

8. A method according to ~~any of~~ claims 1-6, wherein said cells are express shared not immunodominant cancer antigens.

9. A method according to ~~any of~~ claims 1-5 and ~~any of~~ claims 7-8, wherein said cells are Epstein-Barr virus-immortalized B-lymphoblastoid cell lines.

10. A method according to ~~any of~~ claims 1-5 and ~~any of~~ claims 7-8, wherein said cells are Pokeweed mitogen (PWM)-activated B-lymphocytes.

11. A method according to ~~any of~~ claims 1-5 and ~~any of~~ claims 7-8, wherein said cells are CD40 activated B-lymphocytes.

12. A method according to ~~any of~~ claims 1-5 and ~~any of~~ claims 7-8, wherein said cells are Phytohemagglutinin (PHA) + recombinant human interleukin-2 (rhIL-2)-activated PBMC.

13. A method according to ~~any of~~ claims 1-5 and ~~any of~~ claims 7-8, wherein said cells are Phytohemagglutinin (PHA) + recombinant human interleukin-2 (rhIL-2) + pokeweed mitogen (PWM)-activated PBMC.

Error! Reference source not found.

Serial No. unknown

14. A method according to ~~any of claims 1-4 and any of claims 6-8~~, wherein said cells are dendritic cells, monocytes, macrophages.

15. A method according to ~~any of claims 1-4 and any of claims 6-8~~, wherein said cells are CD34+ cells, fibroblasts, stem cells, fibroblasts and cheratinocytes.

16. A method according to ~~any of claims 1-15~~, wherein histone deacetylase inhibitors are used in step d).

17. A method according to ~~any of claim 1-16~~, wherein said DNA hypomethylating agent is selected from 5-aza-cytidine or 5-aza-2'-deoxycytidine.

18. Cells obtainable by the method according to ~~any one of claims 1-17~~.

23. Use according to ~~any of claims 19-22~~, wherein said cells are stored as reservoir of pooled antigens.

28. Vaccine according to claim 27, wherein the cells are used ~~as according to claim 23~~.

29. Vaccine according to claim 27 ~~or 28~~, wherein cellular components ~~according to claim 19~~ are used.

31. An article of manufacture comprising a vaccine according to ~~any of claims 25-29~~ and a pharmaceutical composition suitable for systemic administration of a hypomethylating agent.